Genevant and Tome Collaborate to Develop Gene Editing Therapy for Rare Liver Disorder
January 18, 2024
Rare Daily Staff
Swiss biotech Genevant Sciences and Tome Biosciences have entered into a collaboration and nonexclusive license agreement to combine Genevant’s proprietary LNP technology with Tome’s programmable genomic integration technology to develop an in vivo gene editing treatment for an undisclosed rare monogenic liver disorder.
“Successful delivery is critical to realizing the promise of next-generation gene editing approaches like Tome’s, highlighting the importance of world-class LNP technology,” said Pete Lutwyche, president and Chief Executive Officer of Genevant Sciences.
The terms of the agreement were not disclosed except to state that the total deal value for Genevant is $114.3 million, as well as tiered royalties on future product sales.
Genevant Sciences has an expansive lipid nanoparticle (LNP) patent portfolio, and decades of experience and expertise in nucleic acid drug delivery and development. The company’s scientists have pioneered LNP delivery of nucleic acids for over 20 years, and the company’s LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved systemic RNA-LNP product (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing.
Gene-editing biotech Tome Biosciences develops cell and integrative gene therapies using its programmable genomic integration (PGI) technologies that it says allow for the insertion of any genetic sequence of any size at any location in the genome with site-specific precision.
Pete Lutwyche, president and Chief Executive Officer of Genevant Sciences
Sign up for updates straight to your inbox.